Literature DB >> 16621180

Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection.

A Mann1, A C Marriott, S Balasingam, R Lambkin, J S Oxford, N J Dimmock.   

Abstract

Defective interfering (DI) virus RNAs result from major deletions in full-length viral RNAs that occur spontaneously during de novo RNA synthesis. These RNAs are packaged into virions that are by definition non-infectious, and are delivered to cells normally targeted by the virion. DI RNAs can only replicate with the aid of a coinfecting infectious helper virus, but the small size of DI RNA allows more copies of it to be made than of its full-length counterpart, so the cell produces defective virions in place of infectious progeny. In line with this scenario, the expected lethal disease in an influenza A virus-mouse model is made subclinical by administration of DI virus, but animals develop solid immunity to the infecting virus. Hence DI virus has been called an 'interfering vaccine'. Because interfering vaccine acts intracellularly and at a molecular level, it should be effective against all influenza A viruses regardless of subtype. Here we have used the ferret, widely acknowledged as the best model for human influenza. We show that an interfering vaccine with defective RNAs from an H3N8 virus almost completely abolished clinical disease caused by A/Sydney/5/97 (H3N2), with abrogation of fever and significant reductions in clinical signs of illness. Animals recovered fully and were solidly immune to reinfection, in line with the view that treatment converts the otherwise virulent disease into a subclinical and immunizing infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621180     DOI: 10.1016/j.vaccine.2006.03.004

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

Review 1.  The influenza pandemic of 2009: lessons and implications.

Authors:  Paul Shapshak; Francesco Chiappelli; Charurut Somboonwit; John Sinnott
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

Review 2.  Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals?

Authors:  Nigel J Dimmock; Andrew J Easton
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

3.  Emergence of the virulence-associated PB2 E627K substitution in a fatal human case of highly pathogenic avian influenza virus A(H7N7) infection as determined by Illumina ultra-deep sequencing.

Authors:  Marcel Jonges; Matthijs R A Welkers; Rienk E Jeeninga; Adam Meijer; Peter Schneeberger; Ron A M Fouchier; Menno D de Jong; Marion Koopmans
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

Review 4.  A Virus Is a Community: Diversity within Negative-Sense RNA Virus Populations.

Authors:  Lavinia J González Aparicio; Carolina B López; Sébastien A Felt
Journal:  Microbiol Mol Biol Rev       Date:  2022-06-23       Impact factor: 13.044

5.  Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral.

Authors:  Nigel J Dimmock; Edward W Rainsford; Paul D Scott; Anthony C Marriott
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

6.  Porcine rotavirus bearing an aberrant gene stemming from an intergenic recombination of the NSP2 and NSP5 genes is defective and interfering.

Authors:  Dianjun Cao; Mario Barro; Yasutaka Hoshino
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

7.  Population dynamics of an RNA virus and its defective interfering particles in passage cultures.

Authors:  Kristen A Stauffer Thompson; John Yin
Journal:  Virol J       Date:  2010-09-29       Impact factor: 4.099

8.  Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir.

Authors:  Nigel J Dimmock; Brian K Dove; Bo Meng; Paul D Scott; Irene Taylor; Linda Cheung; Bassam Hallis; Anthony C Marriott; Miles W Carroll; Andrew J Easton
Journal:  Antiviral Res       Date:  2012-10-04       Impact factor: 5.970

9.  Nucleotide-resolution profiling of RNA recombination in the encapsidated genome of a eukaryotic RNA virus by next-generation sequencing.

Authors:  Andrew Routh; Phillip Ordoukhanian; John E Johnson
Journal:  J Mol Biol       Date:  2012-10-13       Impact factor: 5.469

10.  Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established.

Authors:  Nigel J Dimmock; Brian K Dove; Paul D Scott; Bo Meng; Irene Taylor; Linda Cheung; Bassam Hallis; Anthony C Marriott; Miles W Carroll; Andrew J Easton
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.